Table 3.
Unadjusted Rate of Physician-Reported Adherence to Recommendations Against Ovarian Cancer Screening by Patient, Physician, and Practice Characteristics
All physicians (n = 497) | |
---|---|
Total | 71.8 |
Patient characteristics | |
Age (years) | |
35 | 72.4 |
51 | 71.3 |
Race | |
African American | 72.6 |
Caucasian | 70.1 |
Insurance typea | |
Private | 67.8 |
Medicaid | 76.5 |
Requested ovarian cancer screeningb | |
Yes | 63.9 |
No | 79.7 |
Physician and practice characteristics | |
Age (years) | |
30–39 | 78.7 |
40–49 | 73.4 |
50–64 | 66.7 |
Sex | |
Female | 73.8 |
Male | 70.4 |
Specialtyc | |
Family medicine | 72.8 |
Obstetrics-gynecology | 60.5 |
General internal medicine | 76.0 |
Board certification | |
Yes | 73.1 |
No | 58.3 |
Years in practice | |
0–10 | 75.2 |
11–20 | 72.7 |
21+ | 69.6 |
Practice typeb | |
Solo practice | 57.4 |
Group practice or other practice type | 76.3 |
Weekly average number of patients | |
1–60 | 76.9 |
61–90 | 75.6 |
91+ | 65.5 |
Involved in clinical teaching | |
Yes | 72.9 |
No | 70.8 |
Geographic location | |
Small rural/remote rural | 66.8 |
Large rural | 69.0 |
Urban | 72.6 |
Census division | |
New England | 59.5 |
Middle Atlantic | 65.5 |
East North Central | 80.8 |
West North Central | 67.8 |
South Atlantic | 76.2 |
East South Central | 68.0 |
West South Central | 63.4 |
Mountain | 64.2 |
Pacific | 77.0 |
Level of risk taking | |
Low (6–17) | 71.8 |
Medium (18–24) | 71.7 |
High (25+) | 71.8 |
Fear of malpractice | |
Low (2–4) | 73.5 |
Medium (5–7) | 77.2 |
High (8+) | 68.8 |
USPSTF among top three sources of cancer screening informationb | |
Yes | 79.6 |
No | 623 |
NIH/NCI among top three sources of cancer screening informationa | |
Yes | 65.9 |
No | 75.0 |
ACOG among top three sources of cancer screening information | |
Yes | 67.4 |
No | 73.9 |
ACS among top three sources of cancer screening information | |
Yes | 70.6 |
No | 74.0 |
TVU is clinically effective in screening for ovarian cancerb | |
Agree | 48.1 |
Disagree | 81.0 |
CA125 is clinically effective in screening for ovarian cancerb | |
Agree | 40.2 |
Disagree | 79.3 |
Either TVU or CA125 is clinically effective in screening for ovarian cancerb | |
Agree | 47.7 |
Disagree | 82.9 |
p ≤ 0.05
p ≤ 0.001
p ≤ 0.01.
Results were adjusted using weights to represent the specialty distribution of the practicing U.S. physician population of family physicians, general internists, and obstetrician-gynecologists.